Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Idorsia from CHF 17 to CHF 15 and set a neutral rating on the stock in a research note on Tuesday, January 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Idorsia from a buy rating to a hold rating in a research note on Friday, October 21st. Finally, Credit Suisse Group lowered shares of Idorsia from an outperform rating to a neutral rating in a research note on Thursday, November 10th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Idorsia currently has a consensus rating of Hold and a consensus price target of $22.50.
Idorsia Price Performance
IDRSF stock opened at $18.84 on Wednesday. The company’s 50-day simple moving average is $15.08 and its 200-day simple moving average is $14.44. Idorsia has a 52-week low of $11.62 and a 52-week high of $24.30.
Idorsia Company Profile
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
- Get a free copy of the StockNews.com research report on Idorsia (IDRSF)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.